Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sonnet BioTherapeutics Holdings, Inc. (SONN : NSDQ)

• Company Description    Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.25 Daily Weekly Monthly 20 Day Moving Average: 766,046 shares Shares Outstanding: 60.59 (millions) Market Capitalization: $15.40 (millions) Beta: 0.71 52 Week High: $1.68 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.22% -12.65% 12 Week -9.28% 1.96% Year To Date -38.49% -24.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 OVERLOOK CENTER SUITE 102 - PRINCETON,NJ 08540 USA ph: 609-375-2227 fax: 704-366-2463 info@sonnetbio.com http://www.sonnetbio.com

• General Corporate Information    Officers Pankaj Mohan - President; Chief Executive Officer and Chairman Jay Cross - Chief Financial Officer Albert Dyrness - Director Nailesh Bhatt - Director Raghu Rao - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83548R105 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/22 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 60.59 Most Recent Split Date: 4.00 (0.04:1) Beta: 0.71 Market Capitalization: $15.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.79 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 56.25% vs. Previous Quarter: -40.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -26.92% ROE 03/31/22 - -226.37 12/31/21 - -240.79 09/30/21 - -431.43 ROA 03/31/22 - -152.74 12/31/21 - -156.86 09/30/21 - -213.41 Current Ratio 03/31/22 - 2.29 12/31/21 - 4.74 09/30/21 - 4.30 Quick Ratio 03/31/22 - 2.29 12/31/21 - 4.74 09/30/21 - 4.30 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -3,875.60 12/31/21 - -4,121.82 09/30/21 - -5,161.98 Book Value 03/31/22 - 0.14 12/31/21 - 0.27 09/30/21 - 0.37 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©